Drug Industry Antitrust Act, 87-1&2

Drug Industry Antitrust Act, 87-1&2

Author: United States. Congress. Senate. Judiciary

Publisher:

Published: 1961

Total Pages: 1928

ISBN-13:

DOWNLOAD EBOOK

Considers S. 1552 and companion H.R. 6245, the Drug Industry Antitrust Act, to amend the Federal Food, Drug, and Cosmetic Act and Sherman Antitrust Act to establish drug company licensing procedures, to require FDA to certify the effectiveness of all new drugs, to require advertisements sent to physicians to contain FDA warnings on the drug, and to limit drug company rights to exclusive production of patented drugs.


Studies on Competition and Antitrust Issues in the Pharmaceutical Industry

Studies on Competition and Antitrust Issues in the Pharmaceutical Industry

Author: Ann-Kathrin Lehnhausen

Publisher: Springer

Published: 2016-11-14

Total Pages: 95

ISBN-13: 3658165510

DOWNLOAD EBOOK

This publication examines how drug originator manufacturers manage to shield their products from competition. It characterizes the pharmaceutical industry in detail and analyzes actions that violate antitrust laws in the USA and/or the European Union. The publication examines, for example, pay-for-delay strategies, market foreclosure, resale price maintenance, but also mergers and acquisitions, while taking into account market specificities such as the unique research and development process. The study explains why drug prices sometimes remain at elevated levels even after the drug’s patent protection has expired. Knowing the characteristics of such anticompetitive strategies helps customers such as health insurance companies to develop effective counter-strategies.


The Antitrust Enterprise

The Antitrust Enterprise

Author: Herbert HOVENKAMP

Publisher: Harvard University Press

Published: 2009-06-30

Total Pages: 392

ISBN-13: 9780674038820

DOWNLOAD EBOOK

After thirty years, the debate over antitrust's ideology has quieted. Most now agree that the protection of consumer welfare should be the only goal of antitrust laws. Execution, however, is another matter. The rules of antitrust remain unfocused, insufficiently precise, and excessively complex. The problem of poorly designed rules is severe, because in the short run rules weigh much more heavily than principles. At bottom, antitrust is a defensible enterprise only if it can make the microeconomy work better, after accounting for the considerable costs of operating the system. The Antitrust Enterprise is the first authoritative and compact exposition of antitrust law since Robert Bork's classic The Antitrust Paradox was published more than thirty years ago. It confronts not only the problems of poorly designed, overly complex, and inconsistent antitrust rules but also the current disarray of antitrust's rule of reason, offering a coherent and workable set of solutions. The result is an antitrust policy that is faithful to the consumer welfare principle but that is also more readily manageable by the federal courts and other antitrust tribunals.